Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Randomized, Observer-blind, Age-descending, Dose Finding Study to Evaluate the Safety and Immunogenicity of Institut Pasteur Quadrivalent Shigella Vaccine (IP-QSV) for Intramuscular Administration in Healthy Adults/Adolescents, Children and Infants

NCT07666750 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT07666750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07666750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Randomized, Observer-blind, Age-descending, Dose Finding Study to Evaluate the Safety and Immunogenicity of Institut Pasteur Quadrivalent Shigella Vaccine (IP-QSV) for Intramuscular Administration in Healthy Adults/Adolescents, Children and Infants
Lead sponsor
International Vaccine Institute
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
November 30, 2028
Enrollment
370 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

shigella infection